METACARDIS (the acronym of Gut MEtagenomics in CARdiometabolic DISeases) is a major EU-funded research project investigating the role of gut microbes in cardiometabolic diseases. The main investigation approach is metagenomics and the use of clinical and experimental studies to identify relationships between components of the intestinal microbiota and the evolution of heart disease and metabolism.
This 12M€ programme launched in 2012 and coordinated by INSERM, involves 15 partners in 6 European countries. 3 leadership sites having a strong expertise in the cross-disciplinary clinical management of cardiometabolic diseases are set recruit 2,000 patients by mid-2015. ICAN is one of them, together with the Integrated Research and Treatment Center Adiposity Diseases in Leipzig, Germany (IFB) and the Novo Nordisk Foundation Center for Basic Metabolic Research (NNFCBMR) in Copenhagen, Denmark. Additionally, Prof. Karine Clément, Chief Executive Officer of ICAN, is the Scientific Coordinator and one the Principal Investigators of METACARDIS.
If you want to contribute to this research, it is still time to enroll in the clinical protocol, and the new web site provides you with all the recruitment details.